Clearpoint Neuro Stock Earnings Reports

ClearPoint Neuro reported record Q1 2026 revenue of $12.1M, up 43% year-over-year (16% organic). Growth was driven by organic device growth (25%) and the acquisition/integration of IRRAflow (IRRAS assets). Gross margin expanded to 64% (vs. 60% a year ago). Revenue mix: biologics & drug delivery $4.8M (flat YoY), neurosurgery navigation & therapy $5.9M (including $2.1M IRRAflow disposables), and capital equipment & software $1.4M (up 177% YoY). Operating expenses rose (R&D +34% to $4.5M; sales & marketing +75% to $6.7M; G&A +22% to $5.0M) reflecting investments, IRRAS integration, and personnel expansion. Cash was $35.6M at quarter end after ~$8M operating cash burn in Q1; management expects burn to decrease as integration completes. Strategic highlights: continued buildout of the ClearPoint Advanced Laboratories (CAL) for preclinical/benchtop services, first commercial APAC drug-delivery procedure, PRISM Laser system adoption and expanded MRI compatibility, FDA clearance and CE mark for the Velocity Alpha drill, first preclinical runs of a ClearPoint robotic platform (KUKA arm partnership), and integration of IRRAflow (new indwelling dual-lumen catheter) into the drug-delivery portfolio. The company reported 60+ active biopharma partners, 25+ clinical trials across 15+ indications, and 175 active sites using ClearPoint technology with an expectation to exceed 200 sites by year-end. Guidance: 2026 revenue expected in the $52M–$56M range. Management reiterated that IRRAflow could be cash neutral as early as 2027 and emphasized the multi‑pillar growth strategy while noting continued regulatory uncertainty on the biologics/combo-device side of the FDA.